Companies /Healthcare
Bioventus Inc - Class A
NASDAQ: BVS Medical Devices
$13.15
▼ $0.18 (−1.31%) today
Markets closed · 5:35pm ET

Bioventus (BVS) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+60.94%
Avg. EPS surprise
Consecutive EPS beats
BVS vs Market · 30-day return after each reportBVSS&P 500
−16%−8%0%+8%+7.9%+7.2%Q1 25−1.1%+2.5%Q2 25−6.1%+1.6%Q3 25−2.9%−3.2%Q4 25−18.0%+0.7%Q1 26−7.8%+0.1%Q2 26
−16%−8%0%+8%Q1 25Q3 25Q1 26
BVS EPS Trend · estimate vs actualEstimateActual
$0.00$0.07$0.14$0.21$0.02$0.08Q1 25$0.20$0.21Q2 25$0.12$0.15Q3 25$0.22$0.24Q4 25$0.07$0.15Q1 26$0.22$0.22Q2 26$0.16$0.17Q3 26
$0.00$0.07$0.14$0.21Q1 25Q3 25Q1 26Q3 26
BVS Revenue Trend · estimate vs actualEstimateActual
$0$50.0M$100.0M$150.0M$122.7M$123.9MQ1 25$145.9M$147.7MQ2 25$138.2M$138.7MQ3 25$154.9M$157.9MQ4 25$129.9M$132.1MQ1 26$155.6M$153.2MQ2 26$149.5M$142.4MQ3 26
$0$50.0M$100.0M$150.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Bioventus Beat Earnings Estimates?

Bioventus beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

BVS quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Non-GAAP EPS excludes $3,625 thousand of strategic alternatives review costs ($0.04 per share) and a $2.3 million deferred tax valuation allowance removal ($0.03 per share), which benefited GAAP diluted EPS of $0.08. $0.17 est. $0.16 +6.25% $142.4M est. $149.5M −4.73%
Q2 2026 $0.22 est. $0.22 +0.92% $153.2M est. $155.6M −1.56%
Q1 2026 $0.15 est. $0.07 +120.59% $132.1M est. $129.9M +1.69%
Q4 2025 $0.24 est. $0.22 +10.75% $157.9M est. $154.9M +1.91%
Q3 2025 $0.15 est. $0.12 +30.43% $138.7M est. $138.2M +0.34%
Q2 2025 $0.21 est. $0.20 +6.76% $147.7M est. $145.9M +1.23%
Q1 2025 $0.08 est. $0.02 +250.88% $123.9M est. $122.7M +0.95%

Figures from SEC filings and company reports. Not investment advice.